Skip to main content
Premium Trial:

Request an Annual Quote

MediSapiens Lands $1M in Seed Backing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Personalized medicine software company MediSapiens has raised $1 million in seed funding from Veraventure, ETF III, VTT Ventures, and Lifeline Ventures.

The Helsinki-based company provides a software database platform that provides genomic data about cancer and cancer treatments that can be used to develop personalized therapies.

The software is based on technology developed at the VTT Technical Research Centre of Finland, and it serves as host to the VTT's gene expression database, which provides data that oncologists can use to evaluate individual genetic signatures for optimizing treatment.

"The latest research — such as The Cancer Genome Atlas funded by the NIH — demonstrates that every patient's cancer is a complex, unique combination of genetic mutations and abnormally expressed genes," MediSapiens CEO and Co-founder Tommi Pisto said in a statement.

"Making use of the data produced by the global scientific community provides a new and significant opportunity to understand cancer," added Olli Kallioniemi, a MediSapiens board member and director of the Institute for Molecular Medicine in Finland. "Oncologists can benefit when these reference datasets are used to interpret molecular profiling results for individual patients."

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.